---
title: "Pre-market hot trades in US stocks: Sarepta Therapeutics pre-market down 14.47%; Upexi pre-market up 13.26%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/249098970.md"
description: "Sarepta Therapeutics pre-market down 14.47%; Upexi pre-market up 13.26%; Telomir Pharmaceuticals pre-market up 133.88%; Blaize pre-market up 67.66%; ECD Automotive Design pre-market up 42.49%"
datetime: "2025-07-18T08:08:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/249098970.md)
  - [en](https://longbridge.com/en/news/249098970.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/249098970.md)
generator: "portal-rs"
---

# Pre-market hot trades in US stocks: Sarepta Therapeutics pre-market down 14.47%; Upexi pre-market up 13.26%

**Pre-market Hot Trades in US Stocks**

Sarepta Therapeutics is down 14.47% in pre-market trading. Based on recent important news:

1.  On July 17, Sarepta announced a 36% layoff, affecting 500 employees, due to the deaths of two patients related to the gene therapy Elevidys. The FDA required a warning for severe liver damage, and the stock price rose 33% in after-hours trading.

2.  On July 17, RBC Capital lowered Sarepta's target price from $25 to $23, reflecting market concerns about the company's prospects.

3.  On July 17, Sarepta announced a restructuring plan, expecting to save $400 million by 2026, and the stock price rose 57% in after-hours trading.

Upexi is up 13.26% in pre-market trading. Based on recent important news:

1.  On July 17, Upexi announced that its holdings of Solana tokens increased to approximately 1.65 million, driving the stock price up.

2.  On July 15, Upexi completed a $50 million private equity issuance, and the stock price fell 13%.

3.  On July 17, Upexi's Chief Strategy Officer emphasized the high-performance advantages of Solana, boosting market confidence.

**Top Gainers in Pre-market US Stocks**

Telomir Pharmaceuticals is up 133.88% in pre-market trading. Based on recent key news:

1.  On July 17, Telomir Pharmaceuticals released important information through the EDGAR system, leading to a significant stock price increase of 133.88%.

2.  No other relevant news.

3.  No other relevant news.

Blaize is up 67.66% in pre-market trading. Based on recent key news:

1.  On July 17, Blaize announced a strategic partnership with Starshine, expected to generate at least $120 million in revenue within 18 months, driving the stock price up over 50% in after-hours trading.

2.  On July 18, Blaize's hybrid AI platform will be deployed in Asia, further enhancing market confidence.

3.  On July 17, Blaize released partnership details through the EDGAR system, increasing transparency for investors.

ECD Automotive Design is up 42.49% in pre-market trading. Based on recent important news:

1.  On June 23, ECD Automotive Design released a press release regarding the company's strategic growth plan, announcing the successful merger with Humble Imports Inc., enhancing the company's capabilities in automotive design, and driving the stock price up 42.49%.

2.  On June 11, the automotive parts sector experienced a surge, with increased market attention on automotive electronics and autonomous driving, boosting the stock prices of related companies

3.  On June 10th, electric vehicle sales in the Chinese market increased by 51% year-on-year, with the penetration rate rising to 30.2%, driving up the stock prices of related companies

### Related Stocks

- [SRPT.US](https://longbridge.com/en/quote/SRPT.US.md)
- [UPXI.US](https://longbridge.com/en/quote/UPXI.US.md)

## Related News & Research

- [SRPT: Key pipeline data for FSHD and DM1 expected soon, with commercial stabilization underway](https://longbridge.com/en/news/298930329.md)
- [Novartis's failed trial for cholesterol drug leads to broad biopharma selloff](https://longbridge.com/en/news/298331526.md)
- [Sarepta to present at Morgan Stanley Global Healthcare Conference fireside chat](https://longbridge.com/en/news/297558810.md)
- [Wells Fargo Remains a Buy on Sarepta Therapeutics (SRPT)](https://longbridge.com/en/news/295099820.md)
- [Sarepta names former Abbvie president as CEO as Ingram retires](https://longbridge.com/en/news/293938995.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**